Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type

Daisuke Ennishi, Yoshinobu Maeda, Nobuharu Fujii, Eisei Kondo, Katsuji Shinagawa, Kazuma Ikeda, Koichi Ichimura, Tadashi Yoshino, Mitsune Tanimoto

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The prognosis for patients with advanced or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL) is extremely poor. Thus, allogeneic stem cell transplantation (allo-HSCT) should be considered for this disease. However, reports of allo-HSCT for ENKL are limited because of the rarity of the disease. Here, we describe the clinical course of 12 cases of advanced and refractory ENKL treated with allo-HSCT, including five cases with cord blood transplant. With a median follow-up of 13 months (range, 1-168 months), seven patients are alive in remission, five have died, and one treatment-related death occurred. All patients with disease progression at transplant died of disease progression, whereas seven of eight patients with a complete or partial response are long-term survivors. Allo-HSCT is a feasible and promising consolidation therapy for advanced and relapsed ENKL. The disease status before allo-HSCT is well associated with general outcome, and thus induction treatment is very important for this disease.

Original languageEnglish
Pages (from-to)1255-1261
Number of pages7
JournalLeukemia and Lymphoma
Volume52
Issue number7
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Natural Killer T-Cells
T-Cell Lymphoma
Hematopoietic Stem Cell Transplantation
Nose
Disease Progression
Transplants
Stem Cell Transplantation
Fetal Blood
Survivors
Therapeutics

Keywords

  • allogeneic stem cell transplantation
  • cord blood transplant
  • Extranodal NK/T-cell lymphoma
  • nasal type

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type. / Ennishi, Daisuke; Maeda, Yoshinobu; Fujii, Nobuharu; Kondo, Eisei; Shinagawa, Katsuji; Ikeda, Kazuma; Ichimura, Koichi; Yoshino, Tadashi; Tanimoto, Mitsune.

In: Leukemia and Lymphoma, Vol. 52, No. 7, 07.2011, p. 1255-1261.

Research output: Contribution to journalArticle

Ennishi, Daisuke ; Maeda, Yoshinobu ; Fujii, Nobuharu ; Kondo, Eisei ; Shinagawa, Katsuji ; Ikeda, Kazuma ; Ichimura, Koichi ; Yoshino, Tadashi ; Tanimoto, Mitsune. / Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type. In: Leukemia and Lymphoma. 2011 ; Vol. 52, No. 7. pp. 1255-1261.
@article{50c6c35ff7b64b538e25c78d604d27f0,
title = "Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type",
abstract = "The prognosis for patients with advanced or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL) is extremely poor. Thus, allogeneic stem cell transplantation (allo-HSCT) should be considered for this disease. However, reports of allo-HSCT for ENKL are limited because of the rarity of the disease. Here, we describe the clinical course of 12 cases of advanced and refractory ENKL treated with allo-HSCT, including five cases with cord blood transplant. With a median follow-up of 13 months (range, 1-168 months), seven patients are alive in remission, five have died, and one treatment-related death occurred. All patients with disease progression at transplant died of disease progression, whereas seven of eight patients with a complete or partial response are long-term survivors. Allo-HSCT is a feasible and promising consolidation therapy for advanced and relapsed ENKL. The disease status before allo-HSCT is well associated with general outcome, and thus induction treatment is very important for this disease.",
keywords = "allogeneic stem cell transplantation, cord blood transplant, Extranodal NK/T-cell lymphoma, nasal type",
author = "Daisuke Ennishi and Yoshinobu Maeda and Nobuharu Fujii and Eisei Kondo and Katsuji Shinagawa and Kazuma Ikeda and Koichi Ichimura and Tadashi Yoshino and Mitsune Tanimoto",
year = "2011",
month = "7",
doi = "10.3109/10428194.2011.572322",
language = "English",
volume = "52",
pages = "1255--1261",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type

AU - Ennishi, Daisuke

AU - Maeda, Yoshinobu

AU - Fujii, Nobuharu

AU - Kondo, Eisei

AU - Shinagawa, Katsuji

AU - Ikeda, Kazuma

AU - Ichimura, Koichi

AU - Yoshino, Tadashi

AU - Tanimoto, Mitsune

PY - 2011/7

Y1 - 2011/7

N2 - The prognosis for patients with advanced or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL) is extremely poor. Thus, allogeneic stem cell transplantation (allo-HSCT) should be considered for this disease. However, reports of allo-HSCT for ENKL are limited because of the rarity of the disease. Here, we describe the clinical course of 12 cases of advanced and refractory ENKL treated with allo-HSCT, including five cases with cord blood transplant. With a median follow-up of 13 months (range, 1-168 months), seven patients are alive in remission, five have died, and one treatment-related death occurred. All patients with disease progression at transplant died of disease progression, whereas seven of eight patients with a complete or partial response are long-term survivors. Allo-HSCT is a feasible and promising consolidation therapy for advanced and relapsed ENKL. The disease status before allo-HSCT is well associated with general outcome, and thus induction treatment is very important for this disease.

AB - The prognosis for patients with advanced or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL) is extremely poor. Thus, allogeneic stem cell transplantation (allo-HSCT) should be considered for this disease. However, reports of allo-HSCT for ENKL are limited because of the rarity of the disease. Here, we describe the clinical course of 12 cases of advanced and refractory ENKL treated with allo-HSCT, including five cases with cord blood transplant. With a median follow-up of 13 months (range, 1-168 months), seven patients are alive in remission, five have died, and one treatment-related death occurred. All patients with disease progression at transplant died of disease progression, whereas seven of eight patients with a complete or partial response are long-term survivors. Allo-HSCT is a feasible and promising consolidation therapy for advanced and relapsed ENKL. The disease status before allo-HSCT is well associated with general outcome, and thus induction treatment is very important for this disease.

KW - allogeneic stem cell transplantation

KW - cord blood transplant

KW - Extranodal NK/T-cell lymphoma

KW - nasal type

UR - http://www.scopus.com/inward/record.url?scp=79959612774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959612774&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.572322

DO - 10.3109/10428194.2011.572322

M3 - Article

VL - 52

SP - 1255

EP - 1261

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -